---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-054999"
form_type: "8-K"
ticker: "ALKS"
cik: "0001520262"
company_name: "Alkermes plc."
filed_at: "2023-10-25T23:59:59+00:00"
generated_at: "2026-06-09T10:29:31.204612+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Alkermes Q3 2023 revenue $380.9M, GAAP net income $47.8M; reiterates FY guidance; oncology split in Nov

## Summary
- Total Q3 revenues $380.9M vs $252.4M YoY; proprietary product sales up 16% to $231.8M.
- GAAP net income $47.8M ($0.28 diluted EPS) vs GAAP net loss of $64.0M YoY; non-GAAP net income $109.5M ($0.64 diluted EPS).
- LYBALVI net sales $50.7M (+87% YoY); VIVITROL $99.3M (+3%); ARISTADA $81.8M (+8%).
- Cash & investments $995.6M; debt $291.4M; reiterates FY2023 guidance.
- Expects oncology spin-off (Mural) Nov 2023 with $275M; settled VIVITROL patent suit with Teva (generic Jan 2027).

## SEC filing metadata
- accession: 0000950170-23-054999
- form_type: 8-K
- ticker: ALKS
- cik: 0001520262
- company_name: Alkermes plc.
- filed_at: 2023-10-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1520262/000095017023054999/0000950170-23-054999-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1520262/000095017023054999/alks-20231025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-054999
- JSON: https://secwatch.observer/filing/0000950170-23-054999.json
- Plain text: https://secwatch.observer/filing/0000950170-23-054999.txt

## Key facts
- Earnings Releases
  Alkermes plc. updated its three and nine months ended September 30, 2023 guidance (reaffirmed).
  - Period: three and nine months ended September 30, 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: On October 25, 2023, Alkermes plc (the “Company”) announced financial results for the three and nine months ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1520262/000095017023054999/0000950170-23-054999-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.